Jump to content

Search the Community

Showing results for tags 'drug resistance'.



More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • COMMUNITY
    • Announcements, meetings and other resources
  • ADVANCED PROSTATE CANCER FORUMS
    • Primary hormone therapy
    • Secondary hormone therapy
    • Castrate Resistant Prostate Cancer
    • Metastatic
    • Very high risk
    • New agents
    • Every little bit helps
    • Radiation, diagnostic imaging, bones and other prostate cancer topics
    • Articles on other sites
  • MEMBER'S STORIES AND NEEDS
    • My story
    • Any suggestions?
    • The lounge

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Found 5 results

  1. Trial stopped - see below. Men who are on androgen deprivation therapy and who have metastases may be interested in the following Phase 3 clinical trial: A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC (ARMOR3-SV) Details of this trial are available at XXXXXXXXX To be eligible, you must not have been treated with abiraterone, enzalutamide or chemotherapy. You must have detectable AR-V7 (your circulating tumour cells will be tested as part of the eligibility process). If accepted for the trial, you will receive active drugs, not placebos. You will receive either Galeterone or Enzalutamide. Galeterone (TOK-001) is a new steroidal antiandrogen under development by Tokai Pharmaceuticals for the treatment of prostate cancer. It possesses a unique dual mechanism of action, acting as both an androgen receptor antagonist and an inhibitor of CYP17A1, an enezyme required for the biosynthesis of the androgens. Galeterone may benefit men who carry the AR-V7 subtype of Castrate Resistant Prostate Cancer and who therefore do not respond well to treatment with either abiraterone or enzalutamide. The trial is currently recruiting participants at the following Australian trial sites listed below: Peter MacCallum Cancer Centre, 2 St. Andrews Place, East Melbourne, VIC, 3002 North Coast Cancer Institute,Wrights Road, Port Macquarie, NSW, 2444 Ashford Cancer Centre/Adelaide Cancer Centre Research, 520 South Road, Kurralta Park, NSW, 5037 Box Hill Hospital, Monash University and Eastern Health Clinical School, Level 2, 5 Arnold Street, Box Hill, VIC, 3128 Macquarie University, Urology Macquarie University Clinic Suite 304 Level 3, 2 Technology Place, Sydney, NSW, 2109 Cabrini Hospital,Suite 19, 183 Wattletree Rd, Malvern, VIC, 3144, AU ICON Cancer Care, 39 White Street, Southport, QLD 4215 Monash Medical Centre, East Bentleigh, 865 Centre Road, East Bentleigh, VIC, 3165 Peninsula Specialist Centre, 101 George Street, Kippa-Ring, QLD 4021 Princess Alexandra Hospital, Ipswich Road, Woollongabba, QLD, 4102 St. George Private Hospital, Oncology Day Care Centre, 1 South Street, Kogarah, NSW, 2217
  2. A large international study has found that 90 percent of men with advanced prostate cancer have some kind of genetic anomaly that could influence treatment. Inherited defects in DNA repair genes are prevalent in advanced prostate cancer patients regardless of family history, and are associated with poorer responses to hormonal therapy and shorter survival times. Click on this link to read about this study. Click on this link to read a further article in the Prostate Cancer Foundation's NewsPulse newsletter about the study.
  3. "These drugs are already in clinical trials for several types of cancer, and I am excited that our work suggests they could also benefit men with prostate cancer who have otherwise run out of treatment options." At this stage it's only trials in mice. There's a long way to go through clinical trials and regulatory approval before it can be prescribed for human patients. Click on this link to read about the research conducted at the Institute of Cancer Research in London.
  4. Cabazitaxel is a chemotherapy treatment which is used when patients become resistant to chemotherapy treatment with Docetaxel. Cabazitaxel improves overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with Docetaxel. Androgen receptor splice variant 7 (AR-V7) in circulating tumuor cells (CTCs) from mCRPC patients was recently demonstrated to be associated with resistance to Abiraterone and Enzalutamide. A group of Dutch and Belgian researchers investigated whether this was also true for Cabazitaxel. They found that Cabazitaxel was effective even if AR-V7 was present. Reference "Efficacy of Cabazitaxel in Castration-resistant prostate cancer is independent of the presence of AR-V7 in Circulating Tumor Cells" Wendy Ostenk et al Article Information DOI: 10.1016/j.eururo.2015.07.007
  5. AR-V7 is an androgen receptor variant which, if found in the blood stream, disables the effectiveness of either Xtandi/enzalutamide or Zytiga/abiraterone acetate. I have prepared a summary of recent research about AR-V7 which is available at http://tinyurl.com/qbgpezo [Ed - Chuck's paper mentions blood tests for Circulating Tumour Cells (CTC) and AR-V7. These tests are not routinely available in Australia.]
×
×
  • Create New...